Validated Digital Health Biomarkers from Innovative Digital Products
Digital biomarkers generated by mobile devices are becoming increasingly valuable as they offer the potential for deeper and richer health data through continuous, contextual, real-time data gathering surpassing the burdensome sampling and lab testing methods of traditional biomarkers.
By assisting in the collection of robust, clinically meaningful data, we can support accurate outcome reporting, regardless of the therapeutic area or pharmaceutical focus.
Our team has been delivering at the intersection of mobile, data and experience for over last 10 years. We help with product and service design, UX & UI design, software engineering alongside building validated systems that collect and store data.
Our technologists have the domain expertise to guide your CRO. We can illustrate how to design and engineer digital products that will remain consistent when mobile hardware changes (like screen size changes or or changes to the sensor-rich internals of devices) and how you follow human-centred design practices to build genuinely engaging apps that reduce patient drop-off.
Screening
From susceptibility and risk biomarkers, through to predictive biomarkers.
Utilising digital products to detect physical or cognitive changes in healthy patients or the ‘soon unwell’ can provide vital information about disease progression. For example, data relating to patients at risk of developing Alzheimer’s disease can identify early signs of disease before symptoms become apparent, which can establish earlier diagnosis and more proactive management.
Diagnosis
Take physical tests and reimagine them within sensor-rich, internet-connected consumer devices. Diagnose diabetes through the measure of glucose level and mark its progression with pressure readings from blood flow in feet.
Leverage complex sensor reading to measure changes in gait parameters or tremors and understand asprognostic biomarkers for complex neurological conditions, which would usually be evaluated subjectively at a point in time.
Management
Monitoring biomarker data to detect complex post-care deterioration in patients.
Provide data as an objective measure of disease progression both during and post-trial to provide valuable data that will help assert the efficacy of medications and therapies tested in double-blind clinical trials. Patient management and monitoring becomes remote, engaging and impactful with digital product development for biomarkers.
Dr Roger FlintClinician and entrepreneur
Who we work with
Give us a test drive
The best way to know if we are good fit is to meet.
Book a free consultation to discuss.